Meta-regression showed that longer treatment duration was significantly associated with greater ALT reduction (-0.04 SMD per 6 months; <i>p</i> = 0.034).<h4>Conclusion</h4>UDCA demonstrates consistent hepatoprotective and cholestasis-modifying effects in MASLD. The gene discussed is GPT; the disease is cholestasis.